CSF concentrations of cAMP and cGMP are reduced in CJD.

<p>CSF concentrations of cAMP (A) and cGMP (B) in cases with Creutzfeldt-Jakob disease (CJD, n = 15) and control patients (CON, n = 11) measured by LC-MS/MS. Data are means ± SEM, **<i>p</i><0.01, Mann-Whitney test.</p

CSF concentrations of cAMP negatively correlate with tau protein in CJD.

<p>Correlation of tau protein with cAMP (A) or cGMP (B) concentrations in CSF of Creutzfeldt-Jakob disease (CJD) patients. Spearman's rank correlation coefficient (r) and the respective <i>p</i>-values are given.</p

CSF concentrations of cAMP and cGMP are not altered in PD and PDD.

<p>CSF concentrations of cAMP (A) and cGMP (B) in cases with Parkinson's disease (PD, n = 11), PD dementia (PDD, n = 8) and control patients (CON, n = 9) measured by LC-MS/MS. Data are means ± SEM, <i>p</i> = 0.50 (cAMP), <i>p</i> = 0.57 (cGMP), Kruskal-Wallis test.</p

Characteristics of patients included in the study.

<p>Data are means ± SD, Data are missing for.</p>a<p>three,</p>b<p>six and.</p>c<p>one patients.</p><p>CON: control patients, m: male, f: female, S: spinal, B: bulbar, S+B: spinal and bulbar, PRNP: prion protein gene, M: methionine, V: valine.</p

CSF concentrations of cAMP and cGMP are not altered in ALS.

<p>CSF concentrations of cAMP (A) and cGMP (B) in cases with amyotrophic lateral sclerosis (ALS, n = 14) and control patients (CON, n = 14) measured by LC-MS/MS. Data are means ± SEM, <i>p</i> = 0.80 (cAMP), <i>p</i> = 0.48 (cGMP), Mann-Whitney test.</p

Characteristics of potential CSF biomarkers for CJD in ROC analysis.

<p>AUC: area under the curve.</p>1<p>The cut-off was calculated using the Youden index <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0032664#pone.0032664-Baker1" target="_blank">[24]</a>.</p

Cyclic AMP and cGMP are stable in human CSF.

<p>Stability of cAMP and cGMP in human CSF after different handling and storage conditions. A CSF sample was splitted and subjected to the indicated procedures before being measured by LC-MS/MS in triplicate. Data were analysed by a one-way ANOVA followed by Dunnett's multiple comparison tests to compare the different groups against the control. Data are means ± SD, <i>p</i> = 0.58 (cAMP), <i>p</i> = 0.70 (cGMP).</p

Additional file 1 of Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer’s and other neurodegenerative diseases

Additional file 1: Supplementary material. Description of assay parallelism and pre-analytical stability

sj-docx-1-eso-10.1177_23969873241234436 – Supplemental material for Incremental value of serum neurofilament light chain and glial fibrillary acidic protein as blood-based biomarkers for predicting functional outcome in severe acute ischemic stroke

Supplemental material, sj-docx-1-eso-10.1177_23969873241234436 for Incremental value of serum neurofilament light chain and glial fibrillary acidic protein as blood-based biomarkers for predicting functional outcome in severe acute ischemic stroke by Christoph Vollmuth, Cornelia Fiessler, Felipe A Montellano, Alexander M Kollikowski, Fabian Essig, Patrick Oeckl, Lorenzo Barba, Petra Steinacker, Cara Schulz, Kathrin Ungethüm, Judith Wolf, Mirko Pham, Michael K Schuhmann, Peter U Heuschmann, Karl Georg Haeusler, Guido Stoll, Markus Otto and Hermann Neugebauer in European Stroke Journal</p